Agrisera High-Quality Polyclonal and Monoclonal Antibody Services

Agrisera is a Swedish company which specialises in polyclonal and monoclonal antibody production. We take pride in our high service level and our antibodies that really work. We have been in business for nearly 30 years and have close collaboration with research groups and pharmaceutical companies around the globe. Agrisera follows strict quality guidelines and is approved by National Institutes of Health (NIH).

Monoclonal and polyclonal custom made antibodies

Agrisera offer a complete range of services for the production of custom made antibodies, both monoclonals and polyclonals. We can assist in designing or producing the antigen, raising the antibody all the way to a purified and labelled antibody.

Cell fusion developed monoclonals

We have longstanding experience in developing monoclonals, including cell fusion and hybridoma selection as well as scale-up of production using cell cultures. Our antibody shop offers a number of exclusive antibodies produced in collaboration with leading research groups, e.g. Alzheimer’s research antibodies specific to amyloid beta oligomers.

Custom made polyclonals

Agrisera has over the years produced polyclonal antibodies against several thousand different antigens. Custom made polyclonals are produced in rabbit, goat, hen, rat and mice. Our immunization programs are optimised to obtain antibodies of high titre and specificity. We are always willing to discuss different demands regarding the length of the program, antigen doses and administration.

Antigens and peptide synthesized design

Peptides can be designed and synthesized according to your requirements. Agrisera offers a complete service in this area and has longstanding experience in selecting peptides that work in specific applications. We also offer recombinant production of large peptides for immunisation.

Purification and antibody labelling

We perform affinity purification of IgG, IgM and IgY for applications such as immunoprecipitation, immunohistochemistry and antibody labelling. Labelling of antibodies with enzymes for use in ELISA and other immunochemical techniques is performed according to client needs.

Immunogenicity studies

Agrisera also performs immunogenicity studies for pharmaceutical companies. The studies are conducted following strict secrecy and ethical guidelines.

All off-the-shelf antibodies from Agrisera are accompanied with full documentation including instructions of use. Agrisera is approved by the National Institute of Health. The Agrisera NIH assurance number is; A5783-01.

Sendai virus for R&D and drug production

Since 1980 Agrisera have produced Sendai virus, which is used by drug companies for R&D and drug production. The virus production has been carried out in accordance with ever-increasing demands from the drug industry. For more information please contact us.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

PROTEO Biotech AG and ARTES Biotechnology GmbH: Strategic Alliance for Marketing of Elafin in Asia, Africa and South America

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

Address
Agrisera AB

Agrisera Images

Products and Services

Video

White Papers

Press Release

8 March 2011

Fujifilm Corporation and Merck, known as MSD outside the US and Canada, have announced that they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceut

Read more
29 May 2007

ACE Pharmaceuticals today announced that the first patient has entered the Phase III trial also known as the Levamisole trial. This trial was accepted by the EMEA by November 2006. The goal of this trial, which was accepted by the EMEA in November 2006, is to assess the efficacy and sa

Read more
19 June 2006

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

Read more

Regional Offices

Agrisera AB

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.